Caption Management’s Capricor Therapeutics CAPR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$4.66M Buy
193,500
+46,700
+32% +$1.42M 0.02% 609
2026
Q1
$4.46M Sell
146,800
-77,000
-34% -$2.05M 0.03% 562
2025
Q4
$6.46M Sell
223,800
-223,700
-50% -$2.92M 0.04% 438
2025
Q3
$3.23M Sell
447,500
-29,900
-6% -$220K 0.03% 652
2025
Q2
$4.74M Buy
477,400
+327,400
+218% +$3.46M 0.05% 421
2025
Q1
$1.42M Sell
150,000
-426,300
-74% -$5.92M 0.01% 798
2024
Q4
$7.95M Hold
576,300
0.08% 245
2024
Q3
$8.77M Buy
576,300
+270,600
+89% +$1.34M 0.14% 176
2024
Q2
$1.46M Buy
+305,700
New +$1.7M 0.02% 557

Other funds holding CAPR

Caption Management's CAPR Position: Q2 2026 in Review

Caption Management opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 72,000 shares worth $1.73M. The stake represents 0.01% of the portfolio and ranks #949 among its holdings. This is a return to the name: Caption Management previously reported a position in CAPR as recently as Q1 2025.

Caption Management first reported a position in CAPR in Q1 2025 and has held it in 2 quarters since. 169 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Caption Management held 72,000 shares of Capricor Therapeutics worth $1.73M as of Q2 2026.
  • Capricor Therapeutics was a new Caption Management position in Q2 2026.
  • Capricor Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #949 holding.
  • Caption Management first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 169 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.